11.15.05
TriStrata Technology, Inc. (TTI), a Princeton, NJ-based subsidiary of NeoStrata, won a patent infringement suit in November 2003 against Valeant Pharmaceuticals International, formerly ICN Pharmaceuticals. A U.S. District Court jury in Wilmington, DE, found seven claims for the two patents were willfully infringed.
On April 12, the court rejected Valeant’s motion to overturn and issued a permanent injunction prohibiting Valeant from the manufacture, sale and marketing of products covered by the infringed patents, such as the use of alpha hydroxy acids to enhance the therapeutic effect of other substances.
TTI has suits pending against ICN relating to another product line, as well as Mary Kay, BeautiControl and Natural Advantage.
On April 12, the court rejected Valeant’s motion to overturn and issued a permanent injunction prohibiting Valeant from the manufacture, sale and marketing of products covered by the infringed patents, such as the use of alpha hydroxy acids to enhance the therapeutic effect of other substances.
TTI has suits pending against ICN relating to another product line, as well as Mary Kay, BeautiControl and Natural Advantage.